About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 947928, 4 pages
Review Article

Anti-VEGF Therapy in Breast and Lung Mouse Models of Cancers

1Dipartimento di Patologia Generale, Seconda Università degli Studi di Napoli, Via L. De Crecchio, 7, 80138 Napoli, Italy
2Dipartimento di Biologia e Patologia Cellulare e Molecolare, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o, Facoltà di Medicina e Chirurgia di Napoli, Università degli Studi di Napoli “Federico II”, Via Pansini 5, 80131 Napoli, Italy

Received 20 September 2010; Accepted 1 October 2010

Academic Editor: Monica Fedele

Copyright © 2011 Di Domenico Marina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cancer is the second leading cause of death in the world after cardiovascular diseases. Some types of cancer cells often travel to other parts of the body through blood circulation or lymph vessels, where they begin to grow. This process is recognized as metastasis. Angiogenesis is the formation of new blood vessels from existing vessel. Normally angiogenesis is a healthy process, that helps the body to heal wounds and repair damaged body tissues, whereas in cancerous condition this process supports new blood vessels formation that provide a tumor with its own blood supply, nutrients and allow it to grow. The most important proximal factor for angiogenesis is the vascular endothelial growth factor VEGF. Angioinhibition is a form of targeted therapy that uses drugs to stop tumors from making new blood vessels. Therefore, in this paper we analyse the importance of VEGF as target of cancer therapy, analysing murine models.